Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Arcus Biosciences Stock Is Rising Today

By Cory Renauer - Jun 24, 2021 at 11:54AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors expecting Gilead Sciences to license Arcus Biosciences' lead asset could be in for an unpleasant surprise.

What happened

Shares of Arcus Biosciences (RCUS -7.75%), a clinical-stage biopharmaceutical company, are on the move following a progress report for the company's most valuable asset at the moment. Investors hoping Gilead Sciences (GILD 0.65%) will exercise an option to license domvanalimab have driven the stock 14% higher as of 11:29 a.m. EDT on Thursday.

So what 

Earlier this year, Gilead Sciences signed a 10-year agreement to co-develop and co-commercialize a handful of Arcus Biosciences' next-generation cancer therapies. Gilead Sciences still has an option to pay Arcus $275 million for exclusive rights to domvanalimab, one of several anti-Tigit antibodies in clinical-stage testing. 

Scientist in the laboratory looking at a bottle.

Image source: Getty Images.

In theory, inhibiting Tigit will make it harder for tumors to hide from the immune system. Early clinical trial results from Arcus Biosciences' peers suggest combining anti-Tigit drugs with other immunotherapies can boost their effectiveness. 

Interest in anti-Tigit antibodies has been high ever since Roche (RHHBY 0.46%) shared compelling data for one called tiragolumab in January. Treatment with tiragolumab plus Tecentriq shrank tumors for 31% of lung cancer patients compared to just 16% of patients who received Tecentriq on its own.

The gain that Arcus Biosciences stock made today wasn't very big for a biotech that could have a blockbuster cancer drug in its late-stage pipeline. That's because the company's being unusually cagey about sharing key details from the ongoing Arc-7 trial.

Now what

Arcus Biosciences described the response rate data as encouraging but declined to share the actual percentages. Clinical-stage biotechnology companies never sit on positive data, so today's nondisclosure should set off alarm bells.

According to the company, patients who received the company's experimental PD-1 blocker, zimberelimab, as a monotherapy performed as well as patients who received Tecentriq and similar immunotherapies in the same setting. Without the actual numbers, though, investors have to assume adding domvanalimab to zimberelimab didn't double patient response rates.

The disturbing nondisclosure Arcus Biosciences made today doesn't necessarily mean that Gilead Sciences won't exercise its option to fully license domvanalimab. Without response rates to be proud of, though, it sure doesn't seem likely. 

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arcus Biosciences, Inc. Stock Quote
Arcus Biosciences, Inc.
$25.23 (-7.75%) $-2.12
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.00 (0.65%) $0.40
Roche Holding AG Stock Quote
Roche Holding AG
$41.55 (0.46%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.